Back to news
13.03.26
Haute Capital Partners Invests in BioCopy AG – AI-Powered Cancer Drug Development
Press Release
Ad hoc announcement pursuant to clause 16 of the BX Listing Rules
Biel/Bienne – March 13, 2026
Haute Capital Partners Invests in BioCopy AG – AI-Powered Cancer Drug Development
Haute Capital Partners SA (BX Swiss: HAUTE) is pleased to announce a strategic investment of CHF 500’000 in BioCopy AG (biocopy.com), a Swiss research-based biotechnology company headquartered in Basel, as part of the company’s capital increase. The investment is structured as a subscription of registered shares of the BioCopy Series A financing round, at a price of CHF 2.45 per share (204’081 registered shares).
BioCopy has established itself as a pioneer in immuno-oncology drug development, combining artificial intelligence, automation and precision screening technologies to develop next-generation biotherapeutics. Its proprietary AI-driven ValidaTe platform enables rapid, parallel profiling of anti-cancer candidates across thousands of cancer-associated and healthy cell targets on a single chip, with the potential to significantly accelerate development timelines and improve efficacy and patient safety.
The company, led by Dr. Matthias Wiedenfels (former CEO of STADA Arzneimittel AG), has a pipeline of five antibody programs targeting peptide-HLA complexes in solid tumors (lung, ovarian, bladder, liver and breast cancer). BioCopy recently raised CHF 9 million as part of their Series A financing round and strengthened its technology platform through the acquisition of lab automation and in silico design capabilities for drug candidate engineering.
“The support of strategic investors such as Haute Capital Partners validates our mission to fundamentally transform cancer drug development through AI and automation”, says Dr. Matthias Wiedenfels, CEO of BioCopy AG.
CEO Statement
Thibault Leroy Bürki, Chief Executive Officer of Haute Capital Partners SA, stated:
"Our investment in BioCopy reflects HAUTE’s conviction that artificial intelligence is fundamentally transforming pharmaceutical research. BioCopy’s ability to drastically reduce cancer drug development timelines while improving efficacy and safety represents a major strategic opportunity. We are excited to support this world-class team in their mission to accelerate access to innovative cancer treatments."
Haute Capital remains committed to delivering superior value to its shareholders while supporting innovative companies that are reshaping their industries.
About Haute Capital Partners SA
Haute Capital Partners SA is a Swiss-listed investment company dedicated to creating long-term value through a diversified and forward-thinking approach. Listed on BX Swiss, it brings together private equity, digital assets, and quoted investments within a transparent and institutional-grade structure, offering both private and professional investors access to advanced financial opportunities in a responsible and innovative way. The company's registered shares are listed on the BX Swiss:
Ticker: HAUTE | ISIN: CH1115678950 | Valor: 111567895 | www.haute.com
Investor Inquiries
Thibault Leroy Bürki
CEO | Haute Capital Partners SA | +41 32 321 35 35 | tb@haute.com
Media & General inquiries
Haute Capital Partners SA | +41 32 321 35 35 | info@haute.com
DISCLAIMER
This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar communication within the meaning of article 652a, 752 and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the BX Swiss. The listing is being made solely by means of and based on the published securities prospectus (including any amendments thereto, if any). An investment decision regarding the securities of the Company should only be made based on the securities prospectus. The prospectus is available free of charge in Switzerland for 12 months following the first day of trading at HAUTE CAPITAL PARTNERS SA, Plänkestrasse 32, 2502 Biel/Bienne, Switzerland. This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. This communication does not constitute an "offer of securities to the public" within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of the securities in the United States, and does not intend to conduct a public offering of securities in the United States.